Copyright
©The Author(s) 2015.
World J Clin Oncol. Oct 10, 2015; 6(5): 166-173
Published online Oct 10, 2015. doi: 10.5306/wjco.v6.i5.166
Published online Oct 10, 2015. doi: 10.5306/wjco.v6.i5.166
Table 3 Other adverse events
| Toxicity ≥ grade 2 | Placebo | SLM |
| Dermatitis | 0 | 2 |
| Dry mouth | 2 | 0 |
| Dysgeusia | 1 | 2 |
| Anemia | 1 | 0 |
| Leukopenia | 2 | 3 |
| Thrombocytopenia | 0 | 0 |
| Odyno-/dysphagia | 2 | 1 |
| Oral/throat pain | 2 | 0 |
| Phlegm | 1 | 3 |
| Elevated creatinine | 1 | 0 |
| Hearing dysfunction | 1 | 1 |
- Citation: Mix M, Singh AK, Tills M, Dibaj S, Groman A, Jaggernauth W, Rustum Y, Jameson MB. Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck. World J Clin Oncol 2015; 6(5): 166-173
- URL: https://www.wjgnet.com/2218-4333/full/v6/i5/166.htm
- DOI: https://dx.doi.org/10.5306/wjco.v6.i5.166